• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对一名依赖输血的β地中海贫血患儿进行地拉罗司耐受性诱导。

Tolerance induction to deferasirox in a child with transfusion-dependent beta thalassemia.

作者信息

Pondrom Morgane, Monpoux Fabrice, Rocher Fanny, Gastaut Nadia, Bailly-Piccini Carole, Poirée Maryline

机构信息

Unité d'Hémato-Oncologie Infantile. Hôpital de l'Archet 2, 151, route de Saint Antoine de Ginestière, 06202 Nice Cedex 3, France.

Unité d'Hémato-Oncologie Infantile. Hôpital de l'Archet 2, 151, route de Saint Antoine de Ginestière, 06202 Nice Cedex 3, France.

出版信息

Arch Pediatr. 2021 Jan;28(1):101-103. doi: 10.1016/j.arcped.2020.10.010. Epub 2020 Nov 26.

DOI:10.1016/j.arcped.2020.10.010
PMID:33250331
Abstract

Beta thalassemias are autosomal recessive hemoglobin disorders related to a defect in the beta-globin chain production. Most of the major forms of beta-thalassemia are transfusion dependent leading to iron overload. Today, three iron chelators are available in France. We report the case of a patient suffering from β major transfusion-dependent thalassemia who presented with severe skin reactions to deferoxamine and deferasirox as well as with agranulocytosis after deferiprone administration. The patient benefited from successful tolerance induction to deferasirox. With the increasing number of children suffering from iron overload, we believe that our protocol can be useful to pediatric hematology teams confronted with multiple iron chelator reactions.

摘要

β地中海贫血是一种常染色体隐性血红蛋白疾病,与β珠蛋白链生成缺陷有关。大多数主要形式的β地中海贫血依赖输血,会导致铁过载。如今,法国有三种铁螯合剂可供使用。我们报告了一例患有重度输血依赖型β地中海贫血的患者,该患者对去铁胺和地拉罗司出现了严重的皮肤反应,并且在服用去铁酮后出现了粒细胞缺乏症。该患者成功诱导了对地拉罗司的耐受性。随着患铁过载的儿童数量不断增加,我们认为我们的方案对面临多种铁螯合剂反应的儿科血液学团队可能有用。

相似文献

1
Tolerance induction to deferasirox in a child with transfusion-dependent beta thalassemia.对一名依赖输血的β地中海贫血患儿进行地拉罗司耐受性诱导。
Arch Pediatr. 2021 Jan;28(1):101-103. doi: 10.1016/j.arcped.2020.10.010. Epub 2020 Nov 26.
2
Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial.去铁酮与地拉罗司治疗依赖输血的血红蛋白病儿科患者的疗效和安全性评估(DEEP-2):一项多中心、随机、开放标签、非劣效性3期试验。
Lancet Haematol. 2020 Jun;7(6):e469-e478. doi: 10.1016/S2352-3026(20)30100-9.
3
Comparative Efficacy and Safety Between Deferiprone and Deferasirox with Special Reference to Serum Ferritin Level and Cardiac Function in Bengali β-Thalassemia Major Children.比较去铁酮和地拉罗司在孟加拉β-地中海贫血症儿童中的疗效和安全性,特别关注血清铁蛋白水平和心脏功能。
Hemoglobin. 2021 Sep;45(5):296-302. doi: 10.1080/03630269.2021.1999258. Epub 2021 Nov 10.
4
Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.不同铁螯合剂对埃及铁过载β地中海贫血患儿的治疗效果。
Infect Disord Drug Targets. 2015;15(2):98-105. doi: 10.2174/1871526515666150724111721.
5
Comparison of Yearly Cost Related to Complications Between Deferasirox and Deferiprone Monotherapy in Thalassemia.地拉罗司与地拉罗酮单药治疗地中海贫血相关并发症的年费用比较。
J Pediatr Hematol Oncol. 2024 Aug 1;46(6):e402-e405. doi: 10.1097/MPH.0000000000002894. Epub 2024 Jun 4.
6
Successful desensitization to deferasirox in a paediatric patient with β-Thalassaemia major.一名重型β地中海贫血患儿成功实现对地拉罗司的脱敏治疗。
Pediatr Allergy Immunol. 2017 Mar;28(2):199-201. doi: 10.1111/pai.12677. Epub 2016 Dec 8.
7
Efficacy And Tolerability Of Oral Iron Chelator, Deferasirox.口服铁螯合剂地拉罗司的疗效和耐受性。
J Ayub Med Coll Abbottabad. 2021 Apr-Jun;33(2):207-212.
8
Effectiveness of Deferasirox in Pediatric Thalassemia Patients: Experience from a Tertiary Care Hospital of Odisha.地拉罗司治疗小儿地中海贫血患者的有效性:来自奥里萨邦一家三级护理医院的经验。
Indian J Pharmacol. 2020 May-Jun;52(3):172-178. doi: 10.4103/ijp.IJP_68_18. Epub 2020 Aug 4.
9
Therapeutic mechanism of combined oral chelation therapy to maximize efficacy of iron removal in transfusion-dependent thalassemia major - a pilot study.联合口服螯合疗法以最大限度提高输血依赖型重型地中海贫血中铁去除效果的治疗机制 - 一项初步研究。
Expert Rev Hematol. 2019 Apr;12(4):265-272. doi: 10.1080/17474086.2019.1593823. Epub 2019 Mar 28.
10
A 15-years follow-up of deferasirox in beta-thalassaemia major patients with iron overload.对重型β地中海贫血铁过载患者使用地拉罗司进行的15年随访。
Br J Haematol. 2020 Nov;191(3):e81-e83. doi: 10.1111/bjh.17035. Epub 2020 Sep 18.

引用本文的文献

1
Successful case of deferasirox slow desensitization in adults.成人地拉罗司缓慢脱敏成功案例。
Allergol Select. 2024 Aug 19;8:278-282. doi: 10.5414/ALX02501E. eCollection 2024.